Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.250NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.63NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.27NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.130NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.44NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.8 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.7 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.41NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.90 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.23NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.30NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.1.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.87NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.33NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.46NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.58 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.26NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.31NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CP.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBGNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.98 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EF.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XPNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DN.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.1.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.3.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CQ.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EC.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.52NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.469NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.80 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.43.8 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.128 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.220NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.58NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.258.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.438NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.257NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.5.4 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.323NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.105 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.4.4 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.4.9 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used